115 related articles for article (PubMed ID: 35040385)
1. Inhibiting L1CAM Reverses Cisplatin Resistance of Triple Negative Breast Cancer Cells by Blocking AKT Signaling Pathway.
Zhang LY; Shen ZX; Guo L
Cancer Invest; 2022 Apr; 40(4):313-324. PubMed ID: 35040385
[TBL] [Abstract][Full Text] [Related]
2. Long noncoding RNA HCP5 contributes to cisplatin resistance in human triple-negative breast cancer via regulation of PTEN expression.
Wu J; Chen H; Ye M; Wang B; Zhang Y; Sheng J; Meng T; Chen H
Biomed Pharmacother; 2019 Jul; 115():108869. PubMed ID: 31028999
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of p90RSK activation sensitizes triple-negative breast cancer cells to cisplatin by inhibiting proliferation, migration and EMT.
Jin Y; Huynh DTN; Kang KW; Myung CS; Heo KS
BMB Rep; 2019 Dec; 52(12):706-711. PubMed ID: 31818359
[TBL] [Abstract][Full Text] [Related]
4. Down-regulating GRP78 reverses pirarubicin resistance of triple negative breast cancer by miR-495-3p mimics and involves the p-AKT/mTOR pathway.
Liu M; Yang J; Lv W; Wang S; Du T; Zhang K; Wu Y; Feng X
Biosci Rep; 2022 Jan; 42(1):. PubMed ID: 34935899
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin-resistant MDA-MB-231 Cell-derived Exosomes Increase the Resistance of Recipient Cells in an Exosomal miR-423-5p-dependent Manner.
Wang B; Zhang Y; Ye M; Wu J; Ma L; Chen H
Curr Drug Metab; 2019; 20(10):804-814. PubMed ID: 31424364
[TBL] [Abstract][Full Text] [Related]
6. RBM8A Depletion Decreases the Cisplatin Resistance and Represses the Proliferation and Metastasis of Breast Cancer Cells via AKT/mTOR Pathway.
Song T; Zhang H
Breast J; 2022; 2022():4576789. PubMed ID: 36105365
[TBL] [Abstract][Full Text] [Related]
7. XPC inhibition rescues cisplatin resistance via the Akt/mTOR signaling pathway in A549/DDP lung adenocarcinoma cells.
Teng X; Fan XF; Li Q; Liu S; Wu DY; Wang SY; Shi Y; Dong M
Oncol Rep; 2019 Mar; 41(3):1875-1882. PubMed ID: 30628719
[TBL] [Abstract][Full Text] [Related]
8. TWIST1 drives cisplatin resistance and cell survival in an ovarian cancer model, via upregulation of GAS6, L1CAM, and Akt signalling.
Roberts CM; Tran MA; Pitruzzello MC; Wen W; Loeza J; Dellinger TH; Mor G; Glackin CA
Sci Rep; 2016 Nov; 6():37652. PubMed ID: 27876874
[TBL] [Abstract][Full Text] [Related]
9. Silencing long non-coding RNA ROR improves sensitivity of non-small-cell lung cancer to cisplatin resistance by inhibiting PI3K/Akt/mTOR signaling pathway.
Shi H; Pu J; Zhou XL; Ning YY; Bai C
Tumour Biol; 2017 May; 39(5):1010428317697568. PubMed ID: 28459375
[TBL] [Abstract][Full Text] [Related]
10. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
Xia A; Li H; Li R; Lu L; Wu X
Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933
[TBL] [Abstract][Full Text] [Related]
11. Reversal of cisplatin resistance by inhibiting PI3K/Akt signal pathway in human lung cancer cells.
Zhang Y; Bao C; Mu Q; Chen J; Wang J; Mi Y; Sayari AJ; Chen Y; Guo M
Neoplasma; 2016; 63(3):362-70. PubMed ID: 26925782
[TBL] [Abstract][Full Text] [Related]
12. TRIM59 knockdown blocks cisplatin resistance in A549/DDP cells through regulating PTEN/AKT/HK2.
He R; Liu H
Gene; 2020 Jul; 747():144553. PubMed ID: 32165307
[TBL] [Abstract][Full Text] [Related]
13. Apatinib enhanced anti-tumor activity of cisplatin on triple-negative breast cancer through inhibition of VEGFR-2.
Gao Z; Shi M; Wang Y; Chen J; Ou Y
Pathol Res Pract; 2019 Jul; 215(7):152422. PubMed ID: 31079851
[TBL] [Abstract][Full Text] [Related]
14. miR-21 modulates cisplatin resistance of gastric cancer cells by inhibiting autophagy via the PI3K/Akt/mTOR pathway.
Gu Y; Fei Z; Zhu R
Anticancer Drugs; 2020 Apr; 31(4):385-393. PubMed ID: 31913198
[TBL] [Abstract][Full Text] [Related]
15. Circular RNA UBAP2 facilitates the cisplatin resistance of triple-negative breast cancer via microRNA-300/anti-silencing function 1B histone chaperone/PI3K/AKT/mTOR axis.
Wang L; Yang X; Zhou F; Sun X; Li S
Bioengineered; 2022 Mar; 13(3):7197-7208. PubMed ID: 35263216
[TBL] [Abstract][Full Text] [Related]
16. Knockdown of long non-coding RNA HOTAIR inhibits cisplatin resistance of gastric cancer cells through inhibiting the PI3K/Akt and Wnt/β-catenin signaling pathways by up-regulating miR-34a.
Cheng C; Qin Y; Zhi Q; Wang J; Qin C
Int J Biol Macromol; 2018 Feb; 107(Pt B):2620-2629. PubMed ID: 29080815
[TBL] [Abstract][Full Text] [Related]
17. MiR-199a-3p enhances breast cancer cell sensitivity to cisplatin by downregulating TFAM (TFAM).
Fan X; Zhou S; Zheng M; Deng X; Yi Y; Huang T
Biomed Pharmacother; 2017 Apr; 88():507-514. PubMed ID: 28126676
[TBL] [Abstract][Full Text] [Related]
18. Transcriptome Profiling of Cisplatin Resistance in Triple-negative Breast Cancer: New Insight into the Role of PI3k/Akt Pathway.
Memar M; Farazmandfar T; Sabaghian A; Shahbazi M; Golalipour M
Curr Mol Med; 2023; 23(6):559-568. PubMed ID: 35585821
[TBL] [Abstract][Full Text] [Related]
19. L1 cell adhesion molecule and epidermal growth factor receptor activation confer cisplatin resistance in intrahepatic cholangiocarcinoma cells.
Yoon H; Min JK; Lee DG; Kim DG; Koh SS; Hong HJ
Cancer Lett; 2012 Mar; 316(1):70-6. PubMed ID: 22088438
[TBL] [Abstract][Full Text] [Related]
20. Lidocaine alleviates cisplatin resistance and inhibits migration of MGC-803/DDP cells through decreasing miR-10b.
Zhang X; Gu G; Li X; Zhang C
Cell Cycle; 2020 Oct; 19(19):2530-2537. PubMed ID: 32892697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
